

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: August 26, 2003

Examiner: To be assigned

For: Use Of Compounds For The Regulation Of Food Intake

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/771,770 filed on January 29, 2001.

The references are as follows:


1. U.S. Patent No. 4,880,783
2. U.S. Patent No. 5,989,584
3. WO 98/42830
4. WO 01/92292
5. Howard et al., Science, Vol. 273, pgs. 974-977 (1996)
6. Kojima et al., Nature, Vol. 402, pgs. 656-660 (1999)
7. Needleman et al., J. Mol. Biol., Vol. 48, pgs. 443-453 (1970)
8. Hansen et al., European Journal of Endocrinology, Vol. 141, pgs. 180-189 (1999)
9. Nakazato et al., Nature, Vol. 409, pgs. 194-198 (2001)
10. "Adenosine", Merck & Co., Inc., Monograph No. 152, CAS Registry No. 58-61-7 (1999)
11. SWISS-PORT sequence date, Kojima sequence 24-99, submitted 1999
12. Ishibashi et al., "Cholecystokinin, motilin....." CA 91:168950 (1979)
13. Garthwaite, "Peripheral motilin administration..." CA 102:198412 (1985)
14. Hsler et al., "Dietary obesity..." CA 103:16720 (1985)
15. Tullin et al., "Adenosine is an agonist of the....." CA 133:233082 (2000)
16. Ando et al., "Administration of erythromycin..." CA 134:4341 (2000)
17. Tolle et al., "In vivo and in vitro..." CA 134:202794 (2001)
18. Ando et al., "Intracerebroventricular injection..." CA 134:205217 (2000)
19. Asakawa et al., "Ghrelin is an appetite..." CA 134:247424 (2001)
20. Tomasetto et al., "Identification of cDNA..." CA 137:1235 (2001)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the references.

The information disclosure statement submitted herewith is being filed on
filing date of application. Therefore, no fee is due.

Date: August 26, 2003

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6150.210-US	Serial No. To be assigned
		Applicant Andersen et al.	
		Filing Date August 26, 2003	Group To be assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,880,783	11/14/89	Mentzer, Jr. et al.	514	46	
	5,989,584	11/23/99	Cook et al.	424	442	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/42840	10/1/98	PCT				
	WO 01/92292	12/6/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Howard et al. Science. Vol. 273. pgs. 974-977 (1996)
		Kojima et al. Nature. Vol. 402. pgs. 656-660 (1999)
		Needleman et al. J. Mol. Biol. Vol. 48. pgs. 443-453 (1970)
		Hansen et al. European Journal of Endocrinology. Vol. 141. pgs. 180-189 (1999)
		Nakazato et al. Nature. Vol. 409. pgs. 194-198 (2001)
		"Adenosine", Merck & Co., Inc., Monograph No. 152, CAS Registry No. 58-61-7 (1999)
		SWISS-PORT sequence date, Kojima sequence 24-99, submitted 1999
		Ishibashi et al. "Cholecystokinin, motilin....." CA 91:168950 (1979)
		Garthwaite. "Peripheral motilin administration..." CA 102:198412 (1985)
		Fisler et al. "Dietary obesity..." CA 103:16720 (1985)
		Tullin et al. "Adenosine is an agonist of the..." CA 133:233082 (2000)

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Andersen et al.

Filing Date August 26, 2003

Group To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Ando et al. "Administration of erythromycin..." CA 134:4341 (2000)
		Tolle et al. "In vivo and in vitro..." CA 134:202794 (2001)
		Tolle et al. "In vivo and in vitro..." CA 134:202794 (2001)
		Asakawa et al. "Ghrelin is an anorectic..." CA 134:247424 (2001)
		Tomasetto et al. "Identification of cDNA..." CA 137:1235 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPF 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.